Podium to Practice: ASH® 2025 – LEUKEMIA: ASC4FIRST Study

Podium to Practice: ASH® 2025 – LEUKEMIA: ASC4FIRST Study

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Speakers

Dr. Lynn Savoie

Dr. Brian Leber

Studies / Trials Discussed

ID 73 – Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.

Studies/trials discussed:

ID 73 – Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study
Tagged